Natera (NASDAQ:NTRA) Downgraded by StockNews.com

StockNews.com cut shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a research note released on Tuesday morning.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group raised their price objective on shares of Natera from $87.00 to $100.00 and gave the stock a buy rating in a report on Thursday, February 29th. Sanford C. Bernstein raised shares of Natera from a market perform rating to an outperform rating and set a $120.00 price objective for the company in a report on Friday, April 5th. The Goldman Sachs Group lifted their price target on shares of Natera from $90.00 to $100.00 and gave the company a buy rating in a report on Monday, April 15th. Raymond James cut shares of Natera from a strong-buy rating to an outperform rating and raised their price objective for the company from $68.00 to $85.00 in a research report on Tuesday, February 20th. Finally, Piper Sandler raised their price objective on shares of Natera from $70.00 to $110.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. According to MarketBeat, Natera has an average rating of Moderate Buy and an average target price of $86.40.

Natera Stock Down 0.2 %

NASDAQ NTRA opened at $91.28 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The company’s fifty day moving average is $87.29 and its two-hundred day moving average is $67.00. Natera has a 52-week low of $36.90 and a 52-week high of $98.82.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, sell-side analysts anticipate that Natera will post -2.35 earnings per share for the current year.

Insider Transactions at Natera

In other news, insider Daniel Rabinowitz sold 35,307 shares of Natera stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the completion of the sale, the insider now owns 204,218 shares in the company, valued at approximately $15,334,729.62. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider John Fesko sold 2,358 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total transaction of $153,482.22. Following the completion of the transaction, the insider now owns 108,494 shares in the company, valued at $7,061,874.46. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Rabinowitz sold 35,307 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the transaction, the insider now owns 204,218 shares of the company’s stock, valued at approximately $15,334,729.62. The disclosure for this sale can be found here. Insiders sold a total of 453,644 shares of company stock worth $36,594,940 in the last quarter. 9.42% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after buying an additional 588,147 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 0.9% in the third quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock valued at $334,388,000 after buying an additional 67,102 shares during the period. Kynam Capital Management LP boosted its holdings in shares of Natera by 3.6% in the third quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock valued at $132,912,000 after buying an additional 103,668 shares during the period. RTW Investments LP boosted its holdings in shares of Natera by 1.5% in the third quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company’s stock valued at $117,341,000 after buying an additional 40,000 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Natera by 52.0% in the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock valued at $111,930,000 after buying an additional 865,404 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.